NEW YORK (Reuters Health)—Biosimilar tumor necrosis factor-alpha inhibitors appear equivalent to the branded original versions, according to a systematic review and meta-analysis. As Dr. G. Caleb Alexander tells Reuters Health by email, “biologic treatments represent a rapidly growing proportion of prescription drug expenditures and thus there is enormous interest in whether or not biosimilar products…
Search results for: inflammatory bowel disease
Ethics Forum: Unexpected Ethical Issues in Private Practice, Clinical Research
Ethical issues that arise in the average rheumatology practice and in clinical research are often straightforward. The AMA Code of Medical Ethics and the Office Practice and Procedures Manual offer useful information.1 In research, the Protocol and Investigators Agreement spells out who you can enroll and how the trial must be conducted. But still—even when…
Rheumatology Coding Corner Question: Physical Examination with Infliximab Infusion
A 12-year-old male established patient with inflammatory bowel disease with associated juvenile spondyloarthropathy returns to the office for a follow-up visit for his infliximab infusion. The patient reports moderate pain in his right hip after walking for extended periods of time or after sports activities. He denies any other joint pain and denies any joint…
The Gut Microbiome Influences Postmenopausal Bone Loss
Bone health has been successfully improved by using probiotics to influence the gut microbiome in postmenopausal women with osteoporosis. New research has gained insight into this process, uncovering that sex steroid depletion increases gut permeability resulting in inflammation and pathology in mice. Treatment with probiotics also prevents this increase in gut permeability and bone loss associated with sex steroid depletion…
Adalimumab & Infliximab Remain in Newborns after Delivery
A recent study showed that, when administered during pregnancy, infliximab takes longer to clear an infant’s system than adalimumab…
Protein Phosphatase 2A and Regulatory T Cell Function Researched
The serine-threonine protein phosphatase 2A (PP2A) enzyme is critical for regulatory T cells to function—without it, they don’t have the ability to suppress effector T cells and can’t protect against autoimmunity, according to new research published in Nature Immunology. Researchers found that conditional knockout mice—in which PP2A expression is knocked out only in regulatory T cells—developed…
NSAIDs Effective for Early Axial Spondyloarthritis
NEW YORK (Reuters Health)—Nonsteroidal anti-inflammatory drugs (NSAIDs) are effective, but underused, in patients with early axial spondyloarthritis, researchers from France report. NSAIDs are the cornerstone of treatment of axial spondyloarthritis, but there is often a trade-off between prescribing doses high enough to decrease pain and other symptoms vs. keeping the doses low enough to decrease…
Long-Term Therapy with Lilly Drug Found to Help Plaque Psoriasis
NEW YORK (Reuters Health)—Aggregated results from three studies of patients with moderate to severe plaque psoriasis show that Eli Lilly’s injectable drug ixekizumab can completely resolve the plaques in about one third of cases after 12 weeks of treatment. And with continued therapy every four weeks, at least half maintained or attained complete resolution of…
TNF Blocking Drugs Persist in Infants after Exposure In-Utero
NEW YORK (Reuters Health)—Babies born to mothers who took anti-tumor necrosis factor (anti-TNF) agents during pregnancy have detectable drug in their bodies up to 12 months of age, new findings show. These infants should therefore not receive live vaccines during their first year of life, Dr. Mette Julsgaard of Aarhus University Hospital in Denmark and…
Golimumab Effective as Maintenance Treatment for Active Ulcerative Colitis
NEW YORK (Reuters Health)—Subcutaneous golimumab every four weeks provides effective long-term maintenance for patients with active ulcerative colitis (UC), according to results from the PURSUIT-SC extension study. The main PURSUIT-M study showed that golimumab treatment maintained clinical responses through Week 54. For most patients, maintenance therapy for UC is required long term. Dr. Peter R….
- « Previous Page
- 1
- …
- 17
- 18
- 19
- 20
- 21
- …
- 30
- Next Page »